Molecular–Histologic Concordance in Kidney Allograft Biopsies: Clinical Utility of Molecular Microscope® Diagnostic System in Real-World Practice

When a kidney is transplanted from one person to another, the body's immune system often views the new organ as an invader. To prevent this, doctors give patients powerful medicines to calm the immune response. However, the immune system can sometimes still attack the kidney, a process called rejection. If this happens, the kidney can fail, and the patient may need to return to dialysis or wait for another transplant. The only way to know for sure if a kidney is being attacked is to take a tiny sample of the tissue, called a biopsy, and look at it under a microscope. Doctors have been doing this for decades, using a standard set of rules to decide what they see. But sometimes, the tissue looks confusing. The signs of an attack might be faint, or the damage might look like it was caused by a virus or a drug side effect rather than the immune system. In these gray areas, doctors often struggle to know whether to increase the anti-rejection medicines or leave them alone, a decision that carries high stakes for the patient's future health.

In a recent study conducted at a medical center in Ljubljana, Slovenia, researchers explored a new way to help solve this puzzle. They combined the traditional microscope examination with a modern molecular test that reads the genetic activity of the cells in the biopsy. This test, known as the Molecular Microscope Diagnostic System, looks for specific patterns of gene activity that act like a fingerprint for rejection. The researchers wanted to see how well this new tool worked alongside the old one in real-world patients, particularly in those difficult cases where the microscope alone was not enough to give a clear answer. They analyzed 219 kidney biopsies taken between 2019 and 2024, comparing the diagnosis made by looking at the tissue structure with the diagnosis made by reading the genetic signals.

The study found that in the vast majority of cases, the two methods agreed with each other. Out of the 219 biopsies, the microscope and the molecular test gave the same answer in 186 of them, which is about 85 percent. This high level of agreement suggests that the new test is reliable and fits well with what doctors already know. However, the real value of the molecular test appeared in the cases where the two methods disagreed or where the microscope view was unclear. In 20 of the biopsies, the tissue looked borderline or ambiguous under the microscope, making it hard for the doctors to decide if rejection was happening. In these specific instances, the molecular test provided the missing piece of information that allowed the medical team to reach a final, confident diagnosis. Without this extra data, those cases might have remained uncertain, leaving doctors to guess at the best treatment.

The researchers also looked at how often the two methods disagreed on whether rejection was present at all. In about 8 percent of the cases, one method said rejection was happening while the other said it was not. The study showed that the molecular test was particularly good at spotting rejection in situations where the microscope might miss it, such as when the tissue sample was small or damaged. For example, in some biopsies where the tissue was too fragmented to be analyzed properly by a pathologist, the molecular test still managed to produce a clear result. This is a significant advantage because in clinical practice, getting a perfect tissue sample is not always possible. The test was able to detect signs of rejection even in samples that were considered inadequate for traditional analysis, ensuring that no patient was left without a diagnosis due to a poor sample.

The team also examined whether the molecular test could help identify a specific type of rejection called antibody-mediated rejection, which is often harder to diagnose than other types. This form of rejection involves antibodies attacking the kidney's blood vessels. Sometimes, the standard markers used to detect this attack are missing, making the diagnosis very difficult. The study found that the molecular test identified signs of this specific rejection in many cases where the standard markers were absent. For instance, in biopsies where the tissue showed inflammation but lacked the usual chemical markers of antibody attack, the molecular test still found the genetic signature of rejection in about three-quarters of the cases. This suggests that the test can reveal active disease that the traditional methods might overlook, potentially allowing doctors to treat patients before their kidney function declines further.

Despite these diagnostic improvements, the study also looked at the short-term outcomes for the patients. The researchers checked how the kidney function changed in the three months after the biopsy and whether the patients experienced graft failure within a year. They found that the differences in kidney function and protein levels over this short period were similar regardless of whether the two diagnostic methods agreed or disagreed. This does not mean the test is useless; rather, it suggests that the immediate future of the kidney is influenced by many factors, and a single test result does not instantly change the trajectory of the organ. The true benefit of the molecular test lies in its ability to clarify the diagnosis in the moment, giving doctors a more solid foundation to make treatment decisions, even if the long-term results take time to show.

Ultimately, the study concludes that the molecular test is a powerful addition to the doctor's toolkit, but it is not a replacement for the traditional microscope. The best approach is to use both methods together. When the microscope view is clear, the two methods usually agree. When the view is cloudy or the tissue is limited, the molecular test acts as a guide, helping to distinguish between an immune attack and other causes of injury. This integrated approach allows medical teams to be more confident in their diagnoses, especially in the complex and uncertain cases that are the most challenging to manage. By combining the visual evidence of the tissue with the genetic story of the cells, doctors can better understand what is happening inside the kidney and tailor the treatment to the specific needs of each patient.